Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes

This study was designed to investigate the effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase N G, N G-asymmetric dimethylarginine (ADMA) in patients and rats with diabetes, and to determine whether elevated endogenous ADMA is implicated in endotheli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Life sciences (1973) 2005-05, Vol.77 (2), p.149-159
Hauptverfasser: Xiong, Yan, Lei, Minxiang, Fu, Sihai, Fu, Yunfeng
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 159
container_issue 2
container_start_page 149
container_title Life sciences (1973)
container_volume 77
creator Xiong, Yan
Lei, Minxiang
Fu, Sihai
Fu, Yunfeng
description This study was designed to investigate the effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase N G, N G-asymmetric dimethylarginine (ADMA) in patients and rats with diabetes, and to determine whether elevated endogenous ADMA is implicated in endothelial dysfunction or macroangiopathy in diabetes. Experimental diabetic model was induced by a single intraperitoneal injection of streptozotocin to male Sprague-Dawley rats and fed for 2-, 4- and 8-week, respectively. Type 2 diabetic patients with different diabetic duration were recruited from Xiangya Hospital. Plasma glucose and serum ADMA levels were measured in both patients and rats. Moreover, endothelium-dependent relaxation of thoracic aortas and some parameters of metabolic control were examined in rats. Serum ADMA concentrations were significantly elevated in type 2 diabetic patients compared with healthy subjects (3.44 ± 0.40 vs 1.08 ± 0.14 μmol/L, n = 50 in diabetic patients and n = 40 in healthy subjects, P < 0.01). The serum levels of ADMA in patients with macroangiopathy were higher than the patients without macroangiopathy (P < 0.01). But no difference was observed in serum ADMA concentrations between groups of patients with different diabetic duration. Similarly, serum levels of ADMA in diabetic rats were also significantly elevated at 2-week duration compared with duration-matched control (3.71 ± 0.20 vs 1.04 ± 0.23 μmol/L, n = 5 ∼ 6, P < 0.01). This elevation of ADMA was retained to 4- and 8-week (3.54 ± 0.76 vs 0.95 ± 0.06 μmol/L for 4-week, 3.21 ± 0.50 vs 1.03 ± 0. 09 μmol/L for 8-week, n = 5 ∼ 6, all P < 0.01) and remained unchanged among three diabetic groups. The elevation of ADMA was accompanied by impairment of endothelium-dependent relaxation and poor metabolic control in diabetic rat. These results first reveal that the extent of elevation in serum ADMA in both rats and patients with diabetes is not proportion with the length of their diabetic duration but rather with the metabolic control of this disease. Elevated endogenous ADMA may be implicated in diabetes-induced endothelial dysfunction and macroangiopathy. This study is helpful to prevention and treatment of diabetic-induced endothelial dysfunction or macroangiopathy.
doi_str_mv 10.1016/j.lfs.2004.10.062
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67788606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320505001335</els_id><sourcerecordid>67788606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-1e7a879df36b3ebb6b47941a19482b6c3af8969f8bee19eb8c04090c3d570bec3</originalsourceid><addsrcrecordid>eNp9kc1qGzEUhUVoSVw3D5BN0aq7ca9GM5oZsgoh_YFAN-1a6OcqlrElV9K0yRPktavBhu4KAqHDuedyPhFyw2DDgIlPu83e5U0L0NX3BkR7QVZsHKYGBGdvyAqg7RreQn9F3uW8A4C-H_gluWL9KFoBsCKvD86hKTQ6ar3SWLyhdk6q-BhoPRnTfKAmBoOhnOS8mDHY-IQhzpn6sPXal5gWPfiSakR89hZpfgllqzJWCz3W2RqRqQqW1qBM__iyPS_F_J68dWqf8fp8r8nPzw8_7r82j9-_fLu_e2wM71lpGA6qFrSOC81Ra6G7YeqYYlM3tloYrtw4icmNGpFNqEcDHUxguO0H0Gj4mnw85R5T_DVjLvLgs8H9XgWsZaQYhnEUld-asJPRpJhzQiePyR9UepEM5EJf7mSlLxf6i1Tp15kP5_BZH9D-mzjjrobbkwFrxd8ek8ymUjFofaq_IG30_4n_CzINmJw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67788606</pqid></control><display><type>article</type><title>Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Xiong, Yan ; Lei, Minxiang ; Fu, Sihai ; Fu, Yunfeng</creator><creatorcontrib>Xiong, Yan ; Lei, Minxiang ; Fu, Sihai ; Fu, Yunfeng</creatorcontrib><description>This study was designed to investigate the effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase N G, N G-asymmetric dimethylarginine (ADMA) in patients and rats with diabetes, and to determine whether elevated endogenous ADMA is implicated in endothelial dysfunction or macroangiopathy in diabetes. Experimental diabetic model was induced by a single intraperitoneal injection of streptozotocin to male Sprague-Dawley rats and fed for 2-, 4- and 8-week, respectively. Type 2 diabetic patients with different diabetic duration were recruited from Xiangya Hospital. Plasma glucose and serum ADMA levels were measured in both patients and rats. Moreover, endothelium-dependent relaxation of thoracic aortas and some parameters of metabolic control were examined in rats. Serum ADMA concentrations were significantly elevated in type 2 diabetic patients compared with healthy subjects (3.44 ± 0.40 vs 1.08 ± 0.14 μmol/L, n = 50 in diabetic patients and n = 40 in healthy subjects, P &lt; 0.01). The serum levels of ADMA in patients with macroangiopathy were higher than the patients without macroangiopathy (P &lt; 0.01). But no difference was observed in serum ADMA concentrations between groups of patients with different diabetic duration. Similarly, serum levels of ADMA in diabetic rats were also significantly elevated at 2-week duration compared with duration-matched control (3.71 ± 0.20 vs 1.04 ± 0.23 μmol/L, n = 5 ∼ 6, P &lt; 0.01). This elevation of ADMA was retained to 4- and 8-week (3.54 ± 0.76 vs 0.95 ± 0.06 μmol/L for 4-week, 3.21 ± 0.50 vs 1.03 ± 0. 09 μmol/L for 8-week, n = 5 ∼ 6, all P &lt; 0.01) and remained unchanged among three diabetic groups. The elevation of ADMA was accompanied by impairment of endothelium-dependent relaxation and poor metabolic control in diabetic rat. These results first reveal that the extent of elevation in serum ADMA in both rats and patients with diabetes is not proportion with the length of their diabetic duration but rather with the metabolic control of this disease. Elevated endogenous ADMA may be implicated in diabetes-induced endothelial dysfunction and macroangiopathy. This study is helpful to prevention and treatment of diabetic-induced endothelial dysfunction or macroangiopathy.</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2004.10.062</identifier><identifier>PMID: 15862600</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adult ; Aged ; Animals ; Arginine - analogs &amp; derivatives ; Arginine - blood ; Diabetes mellitus ; Diabetes Mellitus, Experimental - blood ; Diabetes Mellitus, Experimental - physiopathology ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetic duration ; Endothelial dysfunction ; Female ; Humans ; Macroangiopathy ; Male ; Metabolic control ; Middle Aged ; N G ; N G-asymmetric dimethylarginine ; Nitric Oxide Synthase - antagonists &amp; inhibitors ; Rats ; Rats, Sprague-Dawley ; Streptozocin ; Time Factors ; Vasoconstriction</subject><ispartof>Life sciences (1973), 2005-05, Vol.77 (2), p.149-159</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-1e7a879df36b3ebb6b47941a19482b6c3af8969f8bee19eb8c04090c3d570bec3</citedby><cites>FETCH-LOGICAL-c351t-1e7a879df36b3ebb6b47941a19482b6c3af8969f8bee19eb8c04090c3d570bec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0024320505001335$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15862600$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xiong, Yan</creatorcontrib><creatorcontrib>Lei, Minxiang</creatorcontrib><creatorcontrib>Fu, Sihai</creatorcontrib><creatorcontrib>Fu, Yunfeng</creatorcontrib><title>Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes</title><title>Life sciences (1973)</title><addtitle>Life Sci</addtitle><description>This study was designed to investigate the effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase N G, N G-asymmetric dimethylarginine (ADMA) in patients and rats with diabetes, and to determine whether elevated endogenous ADMA is implicated in endothelial dysfunction or macroangiopathy in diabetes. Experimental diabetic model was induced by a single intraperitoneal injection of streptozotocin to male Sprague-Dawley rats and fed for 2-, 4- and 8-week, respectively. Type 2 diabetic patients with different diabetic duration were recruited from Xiangya Hospital. Plasma glucose and serum ADMA levels were measured in both patients and rats. Moreover, endothelium-dependent relaxation of thoracic aortas and some parameters of metabolic control were examined in rats. Serum ADMA concentrations were significantly elevated in type 2 diabetic patients compared with healthy subjects (3.44 ± 0.40 vs 1.08 ± 0.14 μmol/L, n = 50 in diabetic patients and n = 40 in healthy subjects, P &lt; 0.01). The serum levels of ADMA in patients with macroangiopathy were higher than the patients without macroangiopathy (P &lt; 0.01). But no difference was observed in serum ADMA concentrations between groups of patients with different diabetic duration. Similarly, serum levels of ADMA in diabetic rats were also significantly elevated at 2-week duration compared with duration-matched control (3.71 ± 0.20 vs 1.04 ± 0.23 μmol/L, n = 5 ∼ 6, P &lt; 0.01). This elevation of ADMA was retained to 4- and 8-week (3.54 ± 0.76 vs 0.95 ± 0.06 μmol/L for 4-week, 3.21 ± 0.50 vs 1.03 ± 0. 09 μmol/L for 8-week, n = 5 ∼ 6, all P &lt; 0.01) and remained unchanged among three diabetic groups. The elevation of ADMA was accompanied by impairment of endothelium-dependent relaxation and poor metabolic control in diabetic rat. These results first reveal that the extent of elevation in serum ADMA in both rats and patients with diabetes is not proportion with the length of their diabetic duration but rather with the metabolic control of this disease. Elevated endogenous ADMA may be implicated in diabetes-induced endothelial dysfunction and macroangiopathy. This study is helpful to prevention and treatment of diabetic-induced endothelial dysfunction or macroangiopathy.</description><subject>Adult</subject><subject>Aged</subject><subject>Animals</subject><subject>Arginine - analogs &amp; derivatives</subject><subject>Arginine - blood</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Experimental - blood</subject><subject>Diabetes Mellitus, Experimental - physiopathology</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetic duration</subject><subject>Endothelial dysfunction</subject><subject>Female</subject><subject>Humans</subject><subject>Macroangiopathy</subject><subject>Male</subject><subject>Metabolic control</subject><subject>Middle Aged</subject><subject>N G</subject><subject>N G-asymmetric dimethylarginine</subject><subject>Nitric Oxide Synthase - antagonists &amp; inhibitors</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Streptozocin</subject><subject>Time Factors</subject><subject>Vasoconstriction</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1qGzEUhUVoSVw3D5BN0aq7ca9GM5oZsgoh_YFAN-1a6OcqlrElV9K0yRPktavBhu4KAqHDuedyPhFyw2DDgIlPu83e5U0L0NX3BkR7QVZsHKYGBGdvyAqg7RreQn9F3uW8A4C-H_gluWL9KFoBsCKvD86hKTQ6ar3SWLyhdk6q-BhoPRnTfKAmBoOhnOS8mDHY-IQhzpn6sPXal5gWPfiSakR89hZpfgllqzJWCz3W2RqRqQqW1qBM__iyPS_F_J68dWqf8fp8r8nPzw8_7r82j9-_fLu_e2wM71lpGA6qFrSOC81Ra6G7YeqYYlM3tloYrtw4icmNGpFNqEcDHUxguO0H0Gj4mnw85R5T_DVjLvLgs8H9XgWsZaQYhnEUld-asJPRpJhzQiePyR9UepEM5EJf7mSlLxf6i1Tp15kP5_BZH9D-mzjjrobbkwFrxd8ek8ymUjFofaq_IG30_4n_CzINmJw</recordid><startdate>20050527</startdate><enddate>20050527</enddate><creator>Xiong, Yan</creator><creator>Lei, Minxiang</creator><creator>Fu, Sihai</creator><creator>Fu, Yunfeng</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050527</creationdate><title>Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes</title><author>Xiong, Yan ; Lei, Minxiang ; Fu, Sihai ; Fu, Yunfeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-1e7a879df36b3ebb6b47941a19482b6c3af8969f8bee19eb8c04090c3d570bec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Animals</topic><topic>Arginine - analogs &amp; derivatives</topic><topic>Arginine - blood</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Experimental - blood</topic><topic>Diabetes Mellitus, Experimental - physiopathology</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetic duration</topic><topic>Endothelial dysfunction</topic><topic>Female</topic><topic>Humans</topic><topic>Macroangiopathy</topic><topic>Male</topic><topic>Metabolic control</topic><topic>Middle Aged</topic><topic>N G</topic><topic>N G-asymmetric dimethylarginine</topic><topic>Nitric Oxide Synthase - antagonists &amp; inhibitors</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Streptozocin</topic><topic>Time Factors</topic><topic>Vasoconstriction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xiong, Yan</creatorcontrib><creatorcontrib>Lei, Minxiang</creatorcontrib><creatorcontrib>Fu, Sihai</creatorcontrib><creatorcontrib>Fu, Yunfeng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiong, Yan</au><au>Lei, Minxiang</au><au>Fu, Sihai</au><au>Fu, Yunfeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes</atitle><jtitle>Life sciences (1973)</jtitle><addtitle>Life Sci</addtitle><date>2005-05-27</date><risdate>2005</risdate><volume>77</volume><issue>2</issue><spage>149</spage><epage>159</epage><pages>149-159</pages><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>This study was designed to investigate the effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase N G, N G-asymmetric dimethylarginine (ADMA) in patients and rats with diabetes, and to determine whether elevated endogenous ADMA is implicated in endothelial dysfunction or macroangiopathy in diabetes. Experimental diabetic model was induced by a single intraperitoneal injection of streptozotocin to male Sprague-Dawley rats and fed for 2-, 4- and 8-week, respectively. Type 2 diabetic patients with different diabetic duration were recruited from Xiangya Hospital. Plasma glucose and serum ADMA levels were measured in both patients and rats. Moreover, endothelium-dependent relaxation of thoracic aortas and some parameters of metabolic control were examined in rats. Serum ADMA concentrations were significantly elevated in type 2 diabetic patients compared with healthy subjects (3.44 ± 0.40 vs 1.08 ± 0.14 μmol/L, n = 50 in diabetic patients and n = 40 in healthy subjects, P &lt; 0.01). The serum levels of ADMA in patients with macroangiopathy were higher than the patients without macroangiopathy (P &lt; 0.01). But no difference was observed in serum ADMA concentrations between groups of patients with different diabetic duration. Similarly, serum levels of ADMA in diabetic rats were also significantly elevated at 2-week duration compared with duration-matched control (3.71 ± 0.20 vs 1.04 ± 0.23 μmol/L, n = 5 ∼ 6, P &lt; 0.01). This elevation of ADMA was retained to 4- and 8-week (3.54 ± 0.76 vs 0.95 ± 0.06 μmol/L for 4-week, 3.21 ± 0.50 vs 1.03 ± 0. 09 μmol/L for 8-week, n = 5 ∼ 6, all P &lt; 0.01) and remained unchanged among three diabetic groups. The elevation of ADMA was accompanied by impairment of endothelium-dependent relaxation and poor metabolic control in diabetic rat. These results first reveal that the extent of elevation in serum ADMA in both rats and patients with diabetes is not proportion with the length of their diabetic duration but rather with the metabolic control of this disease. Elevated endogenous ADMA may be implicated in diabetes-induced endothelial dysfunction and macroangiopathy. This study is helpful to prevention and treatment of diabetic-induced endothelial dysfunction or macroangiopathy.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>15862600</pmid><doi>10.1016/j.lfs.2004.10.062</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0024-3205
ispartof Life sciences (1973), 2005-05, Vol.77 (2), p.149-159
issn 0024-3205
1879-0631
language eng
recordid cdi_proquest_miscellaneous_67788606
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Aged
Animals
Arginine - analogs & derivatives
Arginine - blood
Diabetes mellitus
Diabetes Mellitus, Experimental - blood
Diabetes Mellitus, Experimental - physiopathology
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - physiopathology
Diabetic duration
Endothelial dysfunction
Female
Humans
Macroangiopathy
Male
Metabolic control
Middle Aged
N G
N G-asymmetric dimethylarginine
Nitric Oxide Synthase - antagonists & inhibitors
Rats
Rats, Sprague-Dawley
Streptozocin
Time Factors
Vasoconstriction
title Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T02%3A14%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20diabetic%20duration%20on%20serum%20concentrations%20of%20endogenous%20inhibitor%20of%20nitric%20oxide%20synthase%20in%20patients%20and%20rats%20with%20diabetes&rft.jtitle=Life%20sciences%20(1973)&rft.au=Xiong,%20Yan&rft.date=2005-05-27&rft.volume=77&rft.issue=2&rft.spage=149&rft.epage=159&rft.pages=149-159&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2004.10.062&rft_dat=%3Cproquest_cross%3E67788606%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67788606&rft_id=info:pmid/15862600&rft_els_id=S0024320505001335&rfr_iscdi=true